About Civica Foundation
A 501(c)(3) organization that fosters philanthropic support for Civica’s work to manufacture and distribute affordable medications, with an initial commitment to support efforts to bring affordable insulin to all Americans.
Focus Areas
HealthPharmaceuticalsInsulin accessDrug shortagesManufacturing
Who They Fund
communities or organizations experiencing essential supply shortages
Funding Style
direct material supportemergency/short-term reliefrapid-response funding
Topics
alleviation of supply shortages
About Civica Foundation
Civica Foundation centers its giving on one purpose: supporting Civica’s work to manufacture and distribute affordable medications, with an initial commitment to bring affordable insulin to Americans. The foundation operates as a 501(c)(3) public charity and uses philanthropy to back efforts tied to critical medicines and supply continuity. Its active Insulin Initiative Fundraising program is built around biosimilar insulins, including glargine already funded and aspart and lispro in development, with a goal of making insulin available at recommended prices of no more than $30 per vial or $55 per 5-pen pack. Recent grants show the same operational focus in practice. In 2023, Civica Foundation gave $7,552,514 to Civica Inc in Lehi, Utah for alleviating supply shortages, followed by a $6,182,577 grant in 2024 to the same recipient for the same purpose. That pattern points to a funder built around large, targeted support for essential medicines rather than a broad portfolio of unrelated causes. The foundation’s work sits at the intersection of health, pharmaceuticals, insulin access, manufacturing, and supply-chain resilience.
What Civica Foundation Funds
Civica Foundation’s grantmaking is organized around essential medicines and the systems that keep them available. In pharmaceutical manufacturing, it supported Civica Inc with a $7,552,514 grant in 2023 for alleviating supply shortages, tying funding directly to production continuity. The foundation’s insulin work is especially specific. Its Insulin Initiative Fundraising program supports development and launch of Civica biosimilar insulins, including glargine, with aspart and lispro in development, and it frames affordability in terms of recommended prices no higher than $30 per vial or $55 per 5-pen pack. Its stated focus areas also include health, insulin access, drug shortages, and manufacturing. That combination places the foundation squarely in funding for supply-chain and access problems affecting essential consumable items and critical goods.
How Civica Foundation Gives
The reported grant-size distribution is very concentrated at the high end: p25 is $6,525,061, median is $6,867,546, and p75 is $7,210,030. The recent grants show two large awards, one in 2023 and one in 2024, both to the same recipient and both for the same purpose. Civica Foundation is a public charity, not a DAF or a fund that makes program-related investments. It also accepts unsolicited gifts through its Insulin Initiative Fundraising campaign, which is framed as philanthropic partnership support for Civica’s insulin work.
Financial Snapshot
Annual Giving
$27.9M
Total Assets
$11.5M
Total Revenue
$11.7M
Total Expenses
$49.5M
Typical Grant Size
Most grants fall between $6.5M and $7.2M, with a median of $6.9M.
25th Percentile
$6.5M
Median
$6.9M
75th Percentile
$7.2M
Geographic Reach
Local1 state funded
Funding intensity
LowHigh
Headquarters
Unlock Deep Analysis
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeSee Similar Funders
Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeExplore related grant guides
Want a Personalized Pitch for Civica Foundation?
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Free plan available
No contracts
Cancel anytime